Month

Your search for 04/2015 returned 35 results.


EASL 2015 HCV Vaccine Lecture: Dr T. Baumert

  Please click here to view this important EASL 2015 HCV presentation by Thomas F. Baumert, MD. Thomas F. Baumert, MD is Professor of Medicine, head of Inserm Research Unit U1110, Institute of Viral and Liver Diseases, head of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Physician at the Center for Digestive Disease and Hepatol...

Read More


New peer-reviewed, full-text, free HCV articles

See below for a list of new peer-reviewed, full-text, free HCV articles, available free for a limited time, only in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com) New peer-reviewed, full-text article in the section of our Resource Center focused toward Primary Care Providers  Internal PubMed link provided for you ...

Read More


HCV Research Discussion: Dr. Alexander Ploss

What are your interests in the field of HCV Research? My lab is interested in understanding what makes hepatitis C virus (HCV) a virus that infects basically only humans or chimpanzees. There are fairly basic questions that surround the host tropism of the virus, and we want to get a better understanding of the biology, how the virus interacts with its host cell, ...

Read More


EASL Congress HCV Interview: Dr E. Lebovics

Regarding studies that are ongoing, what are you most excited about seeing at EASL? The results of which studies and what types of studies? Dr. Lebovics: Well, now that we are able to eliminate hepatitis C with all oral regimens in about 95% of standard patients, one area of great interest is extending our currently available regimens to special populations, ...

Read More


Treating hepatitis C in difficult-to-treat patients

Interferon-free treatment regimens are highly effective, well-tolerated, and enable clinicians to treat patients with hepatitis C who cannot be treated with interferon-based regimens. In a review article recently published in the journal Nature Reviews Gastroenterology & Hepatology, Peter Ferenci, MD, describes and assesses the application of interferon-free ...

Read More


HCV adapts to host immune response and DAAs

HCV is a rapidly evolving virus with a high mutation rate: adaptation to the host immune response and selection of HCV strains resistant to direct-acting antiviral therapies Hepatitis C virus (HCV) is a positive strand-enveloped ribonucleic acid (RNA) virus, and the single-stranded RNA molecule consists of a large open reading frame encoding a polyprotein precur...

Read More


EASL Abstract Highlights – Dr T. Baumert

EASL Abstract O027 The Expression of Tumor Suppressor PTPRD is Down-Regulated in the Liver of Patients With HCV Infection and in Tumor Lesions of Patients With Hepatocellular Carcinoma Van Renne, F.H.T. Duong, C. Gondeau, D. Calabrese, N. Fontaine, A. Ababsa, S.C. Durand, P. Pessaux, M.H. Heim, T.F. Baumert, J. Lupberger. The International Liver Congress™ ...

Read More


EASL Pre-Congress HCV Interview: Dr R. Brown

Is there any data that is going to be presented at EASL that you’re really excited about? Are there any research studies that are going on right now that you’re really excited about? Dr. Brown: Right now we have two excellent FDA approved options for our genotype 1 Hepatitis C patient, but we have issues with patients who are not genotype 1, or those who have ...

Read More


EASL Pre-Congress HCV Interview: Dr P. Gaglio

What are your thoughts on birth cohort screening for hepatitis C? Should it be mandated by law? Dr. Gaglio: Sure, well I think that birth-cohort screening is an absolutely forward progress in terms of the screening of Hepatitis C, largely due to the fact that risk-based screening has been very ineffective. So, [birth-cohort screening] has been mandated by law and ...

Read More


Focus on Hepatitis B and C risk based screening

Real-life clinical relevance of hepatitis screening in Germany: enhancing risk based screening strategies in primary care settings Effective screening programs are needed to identify HBsAg and anti-HCV positive patients. Population based anti-HCV screening of all adults born between 1945 and 1965 is recommended in the US. For hepatitis B, US-guidelines recommend ...

Read More